Lysophosphatidic Acid Receptor 1 (LPA₁) Antagonists as Potential Migrastatics for Triple Negative Breast Cancer

Area of Science:

• Medicinal Chemistry
• Oncology
• Molecular Pharmacology

Background:

• Metastasis causes 90% of cancer deaths, necessitating novel anti-metastatic (migrastatic) therapies.
• The Lysophosphatidic acid receptor 1 (LPA1) pathway is implicated in promoting cancer metastasis across various cancer types.
• Targeting metastasis-specific pathways remains a critical challenge in developing effective cancer treatments.

Purpose of the Study:

• To synthesize and evaluate novel fluorine-containing triazole derivatives as LPA1 antagonists.
• To assess the potential of these compounds as migrastatic agents for triple-negative breast cancer (TNBC).
• To investigate the mechanism of action of potent LPA1 antagonists in TNBC cells.

Main Methods:

• Synthesis of a series of fluorine-containing triazole derivatives.
• Biological evaluation of synthesized compounds for LPA1 antagonism using cAMP and calcium mobilization assays.
• Assessment of anti-migratory and anti-invasive effects in a TNBC cell line, including cytotoxicity and apoptosis assays.

Main Results:

• Compound 12f demonstrated potent and selective LPA1 antagonism with IC50 values in the nanomolar range.
• Compound 12f significantly inhibited TNBC cell survival, migration, and invasion without inducing apoptosis or cytotoxicity.
• The study identified LPA1 as a viable migrastatic target for TNBC treatment.

Conclusions:

• Fluorine-containing triazole derivatives are effective LPA1 antagonists.
• Compound 12f shows significant potential as a migrastatic drug candidate for triple-negative breast cancer.
• Targeting the LPA1 pathway offers a promising therapeutic strategy to combat cancer metastasis.